MODD vs. LUCD, CODX, LNSR, MDAI, NMTC, FEMY, GBS, ICU, CTCX, and DRIO
Should you be buying Modular Medical stock or one of its competitors? The main competitors of Modular Medical include Lucid Diagnostics (LUCD), Co-Diagnostics (CODX), LENSAR (LNSR), Spectral AI (MDAI), NeuroOne Medical Technologies (NMTC), Femasys (FEMY), GBS (GBS), SeaStar Medical (ICU), Carmell (CTCX), and DarioHealth (DRIO). These companies are all part of the "surgical & medical instruments" industry.
Lucid Diagnostics (NASDAQ:LUCD) and Modular Medical (NASDAQ:MODD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
Lucid Diagnostics presently has a consensus price target of $2.75, indicating a potential upside of 302.58%. Modular Medical has a consensus price target of $4.25, indicating a potential upside of 168.99%. Given Modular Medical's higher possible upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than Modular Medical.
Lucid Diagnostics received 23 more outperform votes than Modular Medical when rated by MarketBeat users. However, 100.00% of users gave Modular Medical an outperform vote while only 59.52% of users gave Lucid Diagnostics an outperform vote.
Lucid Diagnostics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Modular Medical has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
Modular Medical has a net margin of 0.00% compared to Modular Medical's net margin of -2,169.07%. Lucid Diagnostics' return on equity of -235.93% beat Modular Medical's return on equity.
74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 27.5% of Modular Medical shares are held by institutional investors. 4.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 32.3% of Modular Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Lucid Diagnostics had 2 more articles in the media than Modular Medical. MarketBeat recorded 3 mentions for Lucid Diagnostics and 1 mentions for Modular Medical. Lucid Diagnostics' average media sentiment score of 0.76 beat Modular Medical's score of 0.00 indicating that Modular Medical is being referred to more favorably in the news media.
Modular Medical has lower revenue, but higher earnings than Lucid Diagnostics. Modular Medical is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Lucid Diagnostics beats Modular Medical on 8 of the 15 factors compared between the two stocks.
Get Modular Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MODD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Modular Medical Competitors List
Related Companies and Tools
